Tokyo, Feb 28, 2008 - (JCN Newswire) - Eisai Co., Ltd. introduced new product lines, CHOCOLA(R) BB Lucent C (pharmaceutical product, tablets) and CHOCOLA(R) BB Lucent Cream , to its CHOCOLA BB series, Eisai's most popular consumer healthcare brand. The new products will be made available from March 6, 2008.
The CHOCOLA BB series is designed to provide support for women's beauty and wellness through a number of products, such as CHOCOLA BB PLUS(R) for treating acne and other skin troubles. The new CHOCOLA(R) BB Lucent C helps whiten blemishes and brown spots on skin, two of the most common skin problems for women, and the introduction of the product will enable Eisai to respond to more diversified needs related to skin care.
It is widely believed that the oxidation in pigment cells of skin (melanocytes) causes excessive melanin production, which induces blemishes and brown spots on skin. CHOCOLA(R) BB Lucent C , a pharmaceutical product which contains 600mg of vitamin C and 240mg of L-Cysteine in an adult daily dosage (6 tablets per day) promotes whitening of black-melanine with a redox action. Containing a large quantity of L-Cysteine compared with other L-Cysteine consumer products, the CHOCOLA(R) BB Lucent C treats blemishes and brown spots at subepidermal level. Also, natural type vitamin E, vitamin B2 and B6 have been added to improve blood flow in the epidermis and normalize skin metabolism (turnover), and eventually restore healthy skin.
In addition to the CHOCOLA(R) BB Lucent C , Eisai has also introduced a quasi-drug product CHOCOLA(R) BB Lucent C Cream that prevents blemishes and brown spots by suppressing the production of melanin with vitamin C. CHOCOLA(R) BB Lucent C Cream also contains collagen that moisturizes dry skin.
With these new products, Eisai now offers two different CHOCOLA BB product lines, CHOCOLA BB PLUS(R) in a red package for acne and skin troubles ("Red CHOCOLA") and CHOCOLA(R) BB Lucent C in a blue package for blemishes and brown spots ("Blue CHOCOLA"), and as a result, the company aims to increase benefits to wider consumers in society
please visit the link for more details http://www.eisai.co.jp/enews/enews200808.html
About Eisai
Eisai Co., Ltd. (TSE: 4523; ADR: ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.co.jp/index-e.html
Contact:
Corporate Communications
Eisai Co., Ltd
+81-3-3817-5120
Asako Tanaka
Accenture Marketing & Communications
+81-3-5771-9482
info.tokyo@accenture.com
Feb 28, 2008
Source: Eisai
Eisai (TSE: 4523) (U.S: ESALY)
From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary
View more news from these Sectors: Nutrition, Nutrition
|
Print
Alerts
